The treatment of urinary incontinence with Duloxetine

Journal of Obstetrics and Gynaecology

Volumn 28, Issue 2, 2008, Pages 166-169

  Basu, M ^a   Duckett, J ^a  

^a MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

Duloxetine; Stress incontinence; Urinary incontinence

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DULOXETINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; PLACEBO; SEROTONIN;

ALGORITHM; BLADDER CONTRACTION; BLADDER SPHINCTER; BLADDER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MIXED INCONTINENCE; NAUSEA; NOTE; PELVIS FLOOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STRESS INCONTINENCE; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINE INCONTINENCE;

ADRENERGIC UPTAKE INHIBITORS; FEMALE; HUMANS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME; URINARY INCONTINENCE, STRESS;

EID: 41949095995     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610801912931     Document Type: Note

References (32)

1. Abrams P, Andersson KE, Brubaker L. 2005. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapsed and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 3rd ed. Paris: Health Publications Ltd. pp 1589-1630.
2. Athanasiou S, Chaliha C, Digesu A, Sotiropoulou M, Georgoulias N, Khullar V et al. 2007. The effects of duloxetine on urethral function and sphincter morphology. International Urogynecology Journal 18:493-497.
3. Barber MD, Dowsett SA, Mullen KJ, Viktrup L. 2005. The impact of stress urinary incontinence on sexual activity in women. Cleveland Clinic Journal of Medicine 72:225-232.
4. Boy S, Reitz A, Wirth B, Karsenty G, Knapp P, Schurch B. 2005. Facilitatory neuromodulative effect of duloxetine on urethral sphincter motor neurones in healthy females. European Urology Supplement 4:253.
5. Bump R, Benson J, Yalcin I, Zhao Y, Peng D. 2004. Biomechanical and electrophysiological effects of duloxetine in women with stress urinary incontinence. Available at: http://www.continet.org/publications/2004/pdf/0269. pdf.
6. Bump R, Yalcin I, Voss S. 2005. The effect of duloxetine dose escalating and tapering on the incidence of adverse events in women with stress urinary incontinence. Neurourology and Urodynamics 24:582.
7. Bump RC, Norton PA, Zinner NR, Yalcin I. 2003. Mixed urinary incontinence symptoms: urodynamic findings incontinence severity, and treatment response. Obstetrics and Gynecology 102:76-83.
8. Cardozo L, Drutz H, Baygani S, Bump R. 2004. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstetrics and Gynecology 104:511-519.
9. Diokno A, Burgio K, Fultz N, Kinchen K, Obenchain R, Bump R. 2004. Medical and self care practices reported by women with urinary incontinence. American Journal of Managed Care 10:69-78.
10. Dmochowski R, Miklos J, Norton P, Zinner N, Yalcin I, Bump R, for the Duloxetine Study Group. 2003. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Journal of Urology 170:1259-1263.
11. Duckett J, Patil A, Aggarwal I. 2006. The effect of Duloxetine on urethral sphincter morphology. International Urogynecology Journal 17:306-310.
12. Duckett J, Vella M, Kavalakuntla G, Basu M. 2007. Tolerability and efficacy of duloxetine in a non trial situation. British Journal of Obstetrics and Gynaecology 114:543-547.
13. Duckett JRA, Aggarwal I, Patil A. 2006. Duloxetine treatment for women awaiting continence surgery. International Urogynecology Journal 17:563-565.
14. Fleischmann N, Flisser A, Blaivas J, Panagopoulos G. 2003. Sphincteric urinary incontinence: relationship of vesical leak point pressure, urethral mobility and severity of incontinence. Journal of Urology 169:999-1002.
15. Fultz N, Burgio K, Diokno A, Kinchen K, Obenchain R, Bump R. 2003. Burden of stress urinary incontinence for community-dwelling women. American Journal of Obstetrics and Gynecology 189:1275-1282.
16. Fultz N, Herzog A. 2001. Self-reported social and emotional impact of urinary incontinence. Journal of the American Geriatric Society 49:892-899.
17. Ghoniem G, van Leeuwen J, Elser D, Freeman R, Zhao Y, Yalcin I, Bump R, for the duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. 2005. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. Journal of Urology 173:1647-1653.
18. Rochon PA, Gurwitz JH, Sykora K, Mamdani M, Streiner DL, Garfinkel S et al. 2005. Readers guide to critical appraisal of cohort studies:1 Role and design. British Medical Journal 330:895-897.
19. Marriapan P, Ballantyne Z, N'Dow J, Alhasso A. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database System Reviews 2005: 35:CD004752.
20. Michel M, Peters SL. 2004. Role of serotonin and noradrenaline in stress urinary incontinence. BJU International 94:S23-S30.
21. Millard R, Moore K, Rencken R, Yalcin I, Bump R, for the Duloxetine UI Study Group. 2004. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU International 93:311-318.
22. National Collaborating Centre for Women's and Children's Health. 2006. NICE Clinical Guideline No. 40: The management of urinary incontinence in women. London: National Institute for Health and Clinical Excellence.
23. Norton P, Zinner N, Yalcin I, Bump R. 2002. Duloxetine versus placebo for the treatment of stress urinary incontinence. American Journal of Obstetrics and Gynecology 187:40-48.
24. Pajoncini C, Costantini F, Guercini F, Bini V, Porena M. 2003. Clinical and urodynamic features of intrinsic sphincter deficiency. Neurourology and Urodynamics 22:264-268.
25. Thor K, Katofiasc M. 1995. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. Journal of Pharmacology and Experimental Therapeutics 274:1014-1024.
26. van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndele J, Yalcin I, Bump R, for the Duloxetine Urinary Incontinence Study Group. 2004. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. British Journal of Obstetrics and Gynaecology 111:249-257.
27. van Kerrebroeck P. 2004. Duloxetine: an innovative approach for treating stress urinary incontinence. BJU International 94:S31-S37.
28. Vella MV, Duckett JRA. 2007a. Duloxetine for mixed incontinence; does it work? Can urodynamics predict outcome? International Urogynaecology Journal 18:S107-S244.
29. Vella MV, Duckett JRA. 2007b. Duloxetine one year on: are women prepared to take Duloxetine on a long term basis? International Urogynaecology Journal 18:S1-S24.
30. Viktrup L, Bump R. 2003. Pharmacological agents used for the treatment of stress urinary incontinence in women. Current Medical Research and Opinion 19:485-490.
31. Ward K, Hilton P. 2002. Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. British Medical Journal 325:67-70.
32. Yalcin I, Bump RC. 2004. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. American Journal of Obstetrics and Gynecology 191:194-197.